Adicet Bio, Inc.ACETNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-19.60%
↓ 213% below average
Average (39q)
17.38%
Historical baseline
Range
High:257.40%
Low:-79.28%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -19.60% |
| Q2 2025 | 24.59% |
| Q1 2025 | -1.97% |
| Q4 2024 | -11.35% |
| Q3 2024 | 1.36% |
| Q2 2024 | 8.39% |
| Q1 2024 | -3.48% |
| Q4 2023 | -5.38% |
| Q3 2023 | -7.74% |
| Q2 2023 | 6.00% |
| Q1 2023 | 6.96% |
| Q4 2022 | 50.97% |
| Q3 2022 | 2.42% |
| Q2 2022 | 19.99% |
| Q1 2022 | -8.02% |
| Q4 2021 | 22.91% |
| Q3 2021 | 12.34% |
| Q2 2021 | -13.00% |
| Q1 2021 | 26.02% |
| Q4 2020 | 8.29% |
| Q3 2020 | 3.07% |
| Q2 2020 | 23.36% |
| Q1 2020 | 7.82% |
| Q4 2019 | 3.03% |
| Q3 2019 | 8.65% |
| Q2 2019 | 16.31% |
| Q1 2019 | -79.28% |
| Q4 2018 | 257.40% |
| Q3 2018 | -42.89% |
| Q2 2018 | 46.13% |
| Q1 2018 | -18.55% |
| Q4 2017 | 198.59% |
| Q3 2017 | 13.41% |
| Q2 2017 | 12.73% |
| Q1 2017 | 94.41% |
| Q4 2016 | 27.71% |
| Q3 2016 | -36.63% |
| Q2 2016 | -28.55% |
| Q1 2016 | -8.38% |
| Q4 2015 | 76.99% |